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Abstract
Background: Survival of adults with B-Acute Lymphoblastic Leukemia requires accurate risk stratification of patients
in order to provide the appropriate therapy. Contemporary techniques, using clinical and cytogenetic variables are
incomplete for prognosis prediction.
Methods: To improve the classification of adult patients diagnosed with B-ALL into prognosis groups, two
strategies were examined and combined: the expression of the ID1/ID3/IGJ gene signature by RT-PCR and the
immunophenotypic profile of 19 markers proposed in the EuroFlow protocol by Flow Cytometry in bone marrow
samples.
Results: Both techniques were correlated to stratify patients into prognostic groups. An inverse relationship
between survival and expression of the three-genes signature was observed and an immunophenotypic profile
associated with clinical outcome was identified. Markers CD10 and CD20 were correlated with simultaneous
overexpression of ID1, ID3 and IGJ. Patients with simultaneous expression of the poor prognosis gene signature and
overexpression of CD10 or CD20, had worse Event Free Survival and Overall Survival than patients who had either
the poor prognosis gene expression signature or only CD20 or CD10 overexpressed.
Conclusion: By utilizing the combined evaluation of these two immunophenotypic markers along with the poor
prognosis gene expression signature, the risk stratification can be significantly strengthened. Further studies
including a large number of patients are needed to confirm these findings.
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Background
B-ALL is a malignant hematological disorder, with het-
erogeneous clinical, cellular and molecular characteris-
tics, response to therapy and risk of relapse [1, 2].
Biologically, significant advances in the identification
and molecular characterization of genetic alterations
that have an important role in the biology and evolution
of B-ALL have been described [3]. In adult patients, B-
ALL has a poor clinical outcome and low survival rates
with an estimated rate of complete remission (CR) of
75% and disease-free survival (DFS) lower than 30% [4–
7]. Currently, the criteria used to stratify patients into
risk groups at diagnosis is based on a range of variables
that include age at diagnosis, white blood cell count
(WBCC), and cytogenetic and chromosomal alterations
[8, 9]. However, applying these variables for risk assess-
ment may be inadequate because some patients initially
classified as standard risk group with favorable prognos-
tic features, may experience treatment failure, relapse
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and/or death during the course of their disease [10].
Therefore, it is necessary to implement new and better
strategies to be able to properly classify patients into risk
groups from the time of diagnosis, in order to minimize
the risk of both relapse of disease and death by toxicity
to drugs caused by overtreatment.
The analysis of acute leukemia by Flow Cytometry
(FCM), performed in all patients at diagnosis, is of great
significance in routine clinical practice for the classifica-
tion and monitoring of diseases in conjunction with
morphological cytogenetic and molecular analysis [11].
Immunophenotyping has provided relevant information
for the diagnosis, classification and monitoring of
hematological malignancies [12]. Consequently, the as-
sessment of immunophenoype by FCM has become es-
sential and is part of the current World Health
Organization (WHO) classification of hematological
malignancies.
In 2006 the European Union-supported EuroFlow
Consortium (EU-FP6, LSHB-CT-2006-018708) started a
project aimed at the prospective design and evaluation
of panels of antibodies for the diagnosis and classifica-
tion of the most frequent subtypes of leukemias and
lymphomas, in which immunophenotyping has proven
to be relevant [13]. Particularly, in the study of acute
leukemias EuroFlow has contributed in the development
of highly sensitive and standardized FCM. These proto-
cols describe the optimal antibody panels, the design
and evaluation of adequate standard operating proce-
dures (SOPs) for instrument setup, fluorescence com-
pensation and sample preparation and elaboration of
adequate software tools for the overall evaluation of the
phenotypic profiles obtained [13]. These advances have
significantly improved detection of Minimal Residual
Disease (MRD), which assesses response to therapy, and
is an important prognostic indicator.
Another useful tool that has improved the understand-
ing of the pathogenesis and cell biology of acute leuke-
mias is the detection of chromosomal rearrangements.
Various studies have shown that chromosomal rear-
rangements, compared with other molecular techniques,
can determine the prognosis of the disease more accur-
ately [8, 9]. In addition, while many isolated chromo-
somal rearrangements are not able to induce leukemia
in experimental models on their own, the development
of high-resolution profiles of genetic alterations have
further improved the understanding of the genetic basis
of this disease. However, in approximately 50% of B-ALL
cases these chromosomal abnormalities are not ob-
served, suggesting that additional submicroscopic gen-
etic alterations contribute to leukemogenesis [10].
For over a decade the identification of numerical alter-
ations of DNA (gain and loss) has been possible through
molecular techniques such as sequencing and microarrays
[14]. These alterations, which are different from transloca-
tions, can define new disease subtypes and affect the re-
sponse to treatment. Similarly, these alterations may
constitute groups of genetic alterations that together con-
tribute to the establishment and persistence of malignant
clones and clonal evolution of tumor cells [15–20]. Many
of the altered genes encode regulators of lymphoid devel-
opment, cell cycle, tumor suppressors or lymphoid signal-
ing molecules [16, 21].
Some studies using DNA microarray technology are in
progress in the hopes of identifying novel markers of re-
lapse in this patient subgroup. We have recently de-
scribed, for the first time, a 3-gene signature, ID1/ID3/
IGJ, that when highly expressed constitutes a poor prog-
nostic factor in B-ALL adult patients with impact in low
rates of CR, poor OS and shorter EFS [22]. ID family
genes (as ID1 and ID3) are transcription factors, inhibi-
tors of differentiation, and proliferation and cell cycle
regulators [23]. ID genes have been associated with the
biology and pathogenesis of various cancer models, in-
cluding breast, brain, colorectal, prostate, ovary, liver
and pancreas [23, 24]. We hypothesize that our 3-gene
signature could be implemented in routine diagnostic
evaluation to make a more accurate classification of pa-
tients into risk groups. In this work we assessed the rela-
tionship between the molecular signature ID1/ID3/IGJ
and the EuroFlow immunophenotypic features, to deter-
mine the prognosis of patients at the diagnosis in a com-
prehensive and accurate way.
Methods
Patients and samples
Forty-one bone marrow samples and two peripheral
blood samples obtained at diagnosis from 43 B-ALL
adult patients (19 women and 24 men; median age 30;
age range 16–63 years old) were analyzed in this study.
All the individuals provided written informed consent
prior to enrolling in the study, and the study was ap-
proved by the Ethics Committees of the participating
centers (Instituto Nacional de Cancerología and Hospital
Universitario San Ignacio, Bogotá, Colombia). As inclu-
sion criteria, all patients were older than 15 years who
had not received previous chemotherapy treatment. The
diagnosis of B-ALL was confirmed by myelogram ana-
lysis in bone marrow and biopsy aspirates and by immu-
nophenotypic analysis by FCM. The average percentage
of tumor infiltration in bone marrow, detected by FCM,
was 82% (range 20–95%) and in peripheral blood was
189 blasts/uL (range 0–210600). Samples of normal
bone marrow from three patients with diagnosis of solid
tumors in CR, without infiltration of bone marrow and
therefore without hematologic abnormalities, were used
as control.
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Gene expression analysis by Real Time PCR
This analysis was performed as we have previously re-
ported [22]. Briefly, the gene expression signature was
validated by RT-PCR using TaqMan probes to quantify
the expression levels of ID1, ID3 and IGJ mRNA. The
reaction was amplified in a QuantStudio 12 K plex Real-
Time PCR machine (Applied Biosystems). The 2-ΔΔCT
method was used to estimate the fold induction of each
gene using GAPDH and an internal calibrator as con-
trols. RT-PCR assays were done in triplicate.
Immunophenotyping analysis by flow cytomety
Immunophenotype analysis for all samples was performed
using the panel of antibodies recommended and standard-
ized by the European consortium EuroFlow [12]. The B
lymphoblasts phenotype was determined using antibody
combinations in eight different fluorescences (V450,
V500c, FITC, PE, PerCpCy5.5, PECy7, APC, APCH7).
The immunophenotyping panel included backbone
markers present in all tubes, allowing the identification of
the blast population (CD34, CD19 and CD45),
characterization markers useful to distinguish B- develop-
ment patterns (CD20, CD10, kappa, lambda, SmIgM,
cyIgM, CD24, CD22, nTdT, CD58, CD9 and CD38),
myeloid-lineage associated markers, which can be
expressed aberrantly in >80% of B-ALL cases (CD66,
CD13, CD33, CD117) [12, 25]. After the labeling, the sam-
ples were acquired on a BDB FACSCanto II flow cyt-
ometer, using the FACSDiva (BDB) software program.
Fifty thousand events were collected per sample. Data
analysis was performed with the program INFINICYT
TM (Cytognos SL, Salamanca, Spain) to determine the ex-
pression level and mean fluorescence intensity (MFI) for
each of the antigens in the cells. Cell populations were
classified as positive for each marker if the expression
(percentage and MFI) was higher than that was observed
in the negative control (basal autofluorescence basal cells
without antibody). In addition, the MFI of each marker in
leukemic populations was compared to the MFI of the
same marker in normal bone marrow B-cell populations
(normal counterpart) to define whether the analyzed
marker was negative, under-expressed or overexpressed
on the blast population [26]. The panel of 19 markers was
evaluated in 42 patient samples at baseline to confirm the
diagnosis of B-ALL and after induction chemotherapy to
detect the presence of disease (MRD). Instrument setup,
calibration and quality control were performed during the
study using standard commercial reagents (BD Cytometer
Setup and Tracking Beads and BD Comp Beads; BD), ac-
cording to the manufacturer’s instructions.
Statistical analysis
Clustering analyses and heatmaps were performed using
R-project (www.r-project.org), GenomeStudio (Illumina)
and Gene set Enrichment Analysis (GSEA, http://soft-
ware.broadinstitute.org/gsea/index.jsp). Statistical ana-
lysis was performed using SPSS software (version 22 for
windows) and R. p-values that were <0.05 were consid-
ered statistically significant. Survival analyses were esti-
mated by Kaplan-Meier curves and differences between
the survival functions were assessed with the log-rank
test. GraphPad graphic software was used to plot the
immunophenotype markers expression data.
Results
ID1/ID3/IGJ gene expression signature is a variable with
high prognostic impact in adult B-ALL patients
To analyze the prognostic relevance of molecular signa-
tures defined by gene expression profiling in adult B-
ALL, we analyzed 43 primary leukemia samples using
gene expression microarrays and confirmed the most
relevant findings with RT-PCR [22]. Unsupervised clus-
tering analysis according to the three most differentially
expressed genes (ID1, ID3, and IGJ) between responders
and non-responders, revealed the presence of two robust
clusters of samples with different gene expression pro-
files, and with different clinical characteristics. The first
cluster (green bar in Fig. 1a), was characterized by a
gene expression signature related to a good prognosis:
younger patients (<30 years old), lower WBCC (<30.000/
ul), and lower tumor load at diagnosis in both bone mar-
row and peripheral blood at the time of diagnosis; in
addition, 94% of the patients in this group achieved CR.
In contrast, the second cluster, referred here as a pre-
dicted poor prognosis group (red bar in Fig. 1a) included
40% of patients with failure to induction therapy and
was associated with worse prognostic variables. Notably,
the simultaneous over-expression of ID1, ID3 and IGJ
genes was found as an independent prognostic feature
that identifies B-ALL patients with poor EFS (p = 0.001,
Fig. 1b) and OS (p = 0.001, Fig. 1c).
Comparative analysis of immunophenotype of normal
and leukemic cells
Similar to what has been reported in the literature, com-
parative immunophenotype analysis between B-ALL
cases and their normal counterpart, revealed high het-
erogeneity in the expression of the different markers
suggesting the existence of leukemia associated pheno-
types (LAP) [11, 26] in our cohort of patients. Leukemic
lymphoblast cells were characterized by over-expression
(median fluorescence channel) of CD34 and CD10 im-
maturity markers, B lineage markers such as CD19 and
CD24, the lymphocyte common antigen CD45 and aber-
rant expression of myeloid lineage associated marker
CD66. Additionally, blast cells showed higher light scat-
ter characteristics (Forward-Scatter –FSC- and Side-
Scatter –SSC-). Finally, an under-expression of CD38,
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CD117, CD9 and TdT was observed B-ALL cells, as com-
pared to normal B-cell precursors (Additional file 1).
Immunophenotype profile defines risk groups and has
significant prognosis value
To analyze the prognostic relevance of the 19 EuroFlow
immunophenotype markers we used the value of mean
fluorescence channel in combination with light scattering
parameters (FSC and SSC) in the samples of our 42 pa-
tients with adult B-ALL. Unsupervised clustering analysis,
based on the immunophenotype, revealed the presence of
three clusters of samples (Fig. 2a). The first cluster (green
bar) was a group characterized by an immunophenotype
signature associated with a better outcome of the disease
in which all patients (n = 14) achieved CR, only 3 (21%)
presented positive MRD and none of them presented
chromosomal rearrangements at diagnosis or died during
induction treatment. A second cluster, constituted by 21
samples from patients (red bar) with an immunopheno-
type profile associated with a poor prognosis, including 4
(19%) with induction treatment failure, 8 (38%) with MRD
positive and four who died during the induction phase. It
is noteworthy that all patients with t(9;22) + included in
our cohort (n = 5) were included in this group. A third
group of samples (blue bar), represents a small group of
six patients with intermediate outcome compared with
the two extreme groups. In this group, one patient failed
to achieve CR and one more died during induction ther-
apy. Two patients had positive MRD and none of them
had t(9; 22) + .
Fig. 1 Gene expression signature predictor of prognosis. a Unsupervised cluster analysis applied to 43 patients with B-ALL according to the
expression of our 3-genes signature predictor of prognostic. Cluster analysis discriminates 2 different groups (Green bar good prognosis group and
red bar poor prognosis group). Kaplan Meier curves for event-free survival (p = 0.001) b and overall survival (p = 0.001) c according to the presence
of 3-genes signature of poor prognosis (red curve) vs patients without the expression profile of poor prognosis (green curve). The expression profile
of poor prognosis is defined as the simultaneous overexpression of genes ID1, ID3 and IGJ
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Fig. 2 Determination of groups with differential immunophenotypic markers expression. a Unsupervised hierarchical clustering analysis in
diagnosis bone marrow of B-LLA patients according to the expression of the evaluated immunophenotypic markers revealed three main groups
of patients. Green bar (group 1) corresponds to the group with high rates of complete remission, low number of patients with positive MRD and
absence of patients with t (9; 22). While red bar (group 3) represents the group of patients with the highest percentage of induction failures,
positive MRD and all patients with t(9; 22). Blue bar (group 2) represents a small group of patients with intermediate outcome compared with the
two groups in the extremes. CR: complete remission. MRD: minimal residual disease. b Expression levels of immunophenotypic markers in the
two groups formed at the ends of the heatmap with different clinical features (groups 1 and 3). CD45, CD19, CD38 and FSC have lower expression in
group 3 than in group 1. CD10 and Kappa have different high expression in group 3 compared to group 1. The differences are significant (*p = <0.05,
***p = <0.0001). Kaplan Meier curves for event-free survival (c) (p = 0.008) and overall survival (d) (p = 0.559) in the two prognostic groups identified by
immunophenotypic profile. Note that EFS curves showed statistically significant differences, whereas the curves for OS did not
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Comparison of clinical characteristics between the
groups represented by the green and red bars (Group 1
and Group 3, respectively) showed that patients were
significantly different in age (median 25 vs 38 years, re-
spectively). Additionally, WBCC at diagnosis was higher
in group 3, although no statistically significant difference
was found (median: 8830 vs 12,860 leucocytes/μl re-
spectively) (Additional file 2). When we analyze the ex-
pression level of immunophenotypic markers, a
statistically significant higher level of CD10 expression
and reduced expression of CD19, CD38 and CD45 was
observed in the poor prognosis group (Group 3) com-
pared with patients with favorable outcome (Group 1)
(Fig. 2b). Non-significant increased expression of CD20,
CD66 and CD117 markers were also observed in the
group with worse outcome (Additional file 3).
Moreover, survival analysis considering the immunophe-
notypic profile, revealed that over-expression of CD10 and
under-expression of CD19, CD45 and CD38 were associated
with a poor EFS (Fig. 2c) without impact on OS (Fig. 2d).
Gene expression signature is associated with the
immunophenotypical prognostic profile of B-ALL
We then determined whether there was an association
between the identified gene expression signature (ID1,
ID3, IGJ) with the immunophenotypic expression. We
found that patients in group 1 showed significantly lower
levels of expression of the 3 genes (ID1 p = 0.0432, ID3 p =
0.024, IGJ p = 0.0399), when compared with patients be-
longing to group 3 defined by the expression of poor prog-
nosis immunophenotypic markers (Fig. 3a, b, and c). A
correlation analysis was performed to determine if there
was an association between these two molecular signatures
(gene expression and immunophenotype). As can be seen
in Table 1, a significant positive correlation between high
expression of ID1 and lambda and kappa light chains, as
well as a significant negative correlations with CD38 ex-
pression was found. Overexpression of ID3 gene correlated
with decreased in CD38 expression and greater complexity
of tumor cells (SSC). High expression of IGJ also correlated
with elevated expression of lambda chains. The simultan-
eous overexpression of the gene signature ID1, ID3 and IGJ
was correlated with elevated expression of markers associ-
ated with B-cells differentiation and maturation B (CD20,
CD10. p-values in boldface, Table 1). It is interesting to note
that most of the immunophenotypic markers that correlate
with the poor prognosis gene signature are markers that
allow the separation into different prognostic groups.
Clustering analysis defined by immunophenotypic
markers that correlate with gene signature ID1/ID3/IGJ
defines B-ALL patients with poor prognosis
Using an unsupervised hierarchical clustering analysis
based on the expression of immunophenotypic markers
that are most correlated with our gene expression signa-
ture, we observed two groups with differential immuno-
phenotypic profile. The first group (red bar in Fig. 4a)
included patients with poor response to treatment, and
high rates of positive MRD, presented with elevated ex-
pression of CD10, CD20, Lambda and Kappa proteins and
increased in cellular complexity, as well as decreased
CD38 expression. This group, with poor prognostic fea-
tures, was closely associated with gene expression status.
As can be seen at the bottom of Fig. 4a, this group in-
cluded most of the patients with at least 2 of the genes
overexpressed, suggesting a molecular signature of imma-
turity and maturational dyssynchrony.
Analysis of the prognosis of these two different groups
revealed that the group with immunophenotypic and
genetic characteristics of poor prognosis (red bar) had
both lower event-free survival (Fig. 4b, red line) and
lower overall survival (Fig. 4c) than the group with good
prognostic features (green line). As shown in Fig. 4, sta-
tistically significant differences for both EFS and OS (p
= 0.001 and p = 0.045) were found between the two
groups. However, as noted, the difference was much
greater in EFS. Nevertheless, it is important to highlight
that OS curves were better discriminated once the
Fig. 3 Expression levels of genes a ID1 (p = 0.0432), b ID3 (p = 0.024) and c IGJ (p = 0.0399) included in the poor prognosis genetic signature in
groups determined by immunophenotypic expression pattern
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immunophenotypic and genetic characteristics were in-
tegrated (Fig. 4c) than when calculated only accounting
for the immunophenotypic features (Figs. 4c and 2d).
Integration of gene expression signature ID1/ID3/IGJ
together with the over-expression of CD10 and CD20
improves stratification of patients in terms of survival
Due to the significant interaction between differentiation
and maturation markers (CD10, CD20) with gene
expression signature (Table 1), we then categorized pa-
tient molecular characteristics into 3 groups, based on
the expression of the gene signature and the maturation
markers: 1) Absence of both poor prognosis gene ex-
pression signature and absence of CD10 over-expression
(GEP-/CD10-); 2) isolated presence of either poor prog-
nosis gene expression signature or CD10 over-
expression (GEP+ or CD10+), in the absence of the
other; and 3) simultaneous presence of both poor
Table 1 Correlation of immunophenotyping markers and gene expression signature ID1/ID3/IGJ
CD20 CD10 Lambda CD38 Slgmk SSC
Spearman R p-value Spearman R p-value Spearman R p-value Spearman R p-value Spearman R p-value Spearman R p-value
ID3 0.512 0.001 0.454 0.002 0.292 0.06 −0.318 0.04 0.258 0.09 0.343 0.02
ID1 0.298 0.05 0.317 0.04 0.361 0.01 −0.345 0.02 0.358 0.02 0.291 0.06
IGJ 0.337 0.02 0.337 0.01 0.337 0.02 −0.181 0.250 0.178 0.2592 0.121 0.442
Fig. 4 a Heatmap and clustering analysis according to immunophenotypic markers expression correlated with poor prognosis genetic signature.
Note that at the bottom of heatmap it is shown that patients in green group are those with lower altered expression of ID1, ID3, IGJ genes. While
most patients with overexpression of two or more of these genes are included in the red group. Kaplan-Meier curves for event-free survival (p =
0.001) b and overall survival (p = 0.045) c according to the groups defined by the heatmap in a
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prognosis gene expression signature and CD10 overex-
pression (GEP+/CD10+). The GEP-/ CD10- group
showed the best OS and EFS while the GEP+/CD10+
had the worst (Fig. 5a and b, respectively). Interestingly,
the GEP+ or CD10+ showed intermediate values for
both parameters (Fig. 5a and b). Likewise, the same find-
ings were obtained when the analysis was done with
CD20 expression (Fig. 5c and d).
Discussion and conclusions
The current multi-variable risk classification strategies
are unable to adequately stratify patients into risk groups
from the time of diagnosis. Thus, the implementation of
a stronger risk stratification tool should help minimize
both the risk of relapse of disease and death by toxicity
of B-ALL patients. Recently, we identified a signature of
three genes (ID1, ID3 and IGJ), whose simultaneous
over-expression confers a worse prognosis with reduced
EFS and OS in B-ALL adult patients [22] (Fig. 1). In this
study, we wanted to evaluate the role of this gene signa-
ture in combination with EuroFlow immunophenotypic
B-ALL panel as a prognostic tool in adult patients with
B-ALL.
Although Immunophenotyping has provided relevant
information for the diagnosis, classification and monitor-
ing of hematological malignancies, there is scarce infor-
mation about its use as a prognostic parameter. Initially,
we evaluated the ability of immunophenotype to predict
prognosis in B-ALL. We found that the immunophehno-
type correlates with clinical features and outcome. Indi-
viduals who had tumoral lymphoblasts with lower
expression of CD45, CD19, CD38 and high expression
of CD10, CD20 and kappa are patients with poor prog-
nosis and low EFS. This group of patients had low CR
rates, and a high percentage of MRD+. Importantly, this
group included all patients with t(9;22). Additionally,
they have a higher WBCC and median age over 30 years.
The expression of ID1/ID3/IGJ was higher in the
group with the poor prognosis immunophenotype pro-
file and a statistically significant correlation between the
expression of these 3 genes with high expression of
CD10 and CD20 was found. Clustering analysis accord-
ing to the immunophenotypic markers correlated with
the gene expression signature, suggesting that patients
with both poor prognosis gene expression signature and
overexpression of CD10 or CD20, had worse EFS and
worse OS than patients with either one of the profiles.
In general, studies assessing the gene expression pro-
files in B-ALL adult patients are scarce. However, similar
to our results, several studies have experimentally ad-
dressed the idea that ID (ID1, ID2, ID3 and ID4) pro-
teins are markers for prognosis and possible therapeutic
targets in cancer. They have found that high levels of
gene expression, and consequently high levels of ID
Fig. 5 Event free survival (a, c) and overall survival (b, d) of 42 patients according to the categorization defined by the presence of the genetic
signature and CD10 or CD20 expression. p values correspond to differences between gray and yellow curves
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proteins, appear to drive certain human tumors. As a re-
sult, the elevated ID1 and ID3 expression have been as-
sociated with worse prognosis in bladder, breast, brain,
colon, rectum, stomach, kidney, pancreas, prostate,
ovary and liver tumors and also in acute myeloid
leukemia [27–37]. In contrast, few studies have associ-
ated the elevated ID1 and ID3 expression with good
prognosis in models of breast and brain cancer [38, 39].
In turn, the IGJ gene, which was also found over-
expressed in our group with poor response to induction
therapy, has been reported as part of a poor prognosis
signature in B-ALL pediatric patients; interestingly, they
had high Hispanic/Latino ethnicity, low 4-years event-
free survival and high frequency of positive MRD [40].
Our findings demonstrate for the first time, that in
addition to serving as a diagnostic tool, the immunophe-
notypic panel for B-ALL standardized by EuroFlow, may
also have implications for better prognostic classification
of patients, especially when used association with the
gene expression profile of tumor cells. In this regard, the
differential analysis of immunophenotype shows that
there is heterogeneity in the expression of different
markers evaluated and these are associated with the sur-
vival of patients and with the poor prognosis gene ex-
pression signature. The presence of CD38 (>30%) is
associated with worse prognosis in mature B-cell tumors
like B-chronic lymphoid leukemia and in hairy cell
leukemia, T and NK lymphoma [41, 42]. However, our
work and another report on hematopoietic tumors of B-
ALL pediatric Colombian patients [26], describes an
under-expression of CD38 in the group of patients with
poor prognosis. Similar to our findings, Quijano et al.
[26] reported that higher FSC (larger size) was associated
with patients with good prognostic. Expression of CD45,
protein phosphatases that regulates various cellular func-
tions and signaling pathways, has been reported low or
negative in patients with chromosomal aberrations as
t(12;21), t(4;11), hyperdiploidy, t(9;22), t(1;19) [43],
which is consistent with our finding of reduced expres-
sion of this molecule in the group with poor prognostic
features.
Regarding immunophenotypic markers associated with
poor prognosis gene expression signature, patients with
positive gene signature ID1/ID3/IGJ and poor outcome
of the disease, showed over-expression of CD10 and
CD20. It has been previously reported that over-
expression of CD10 in patients with B-ALL is associated
with the presence of poor prognosis genetic abnormal-
ities as t(9; 22) [43]. Similarly, CD10 has been associated
with worse prognosis in patients with melanoma [44]
and high-grade malignancy and worse outcome in pan-
creatic cancer, gastric, colorectal [45], liver [46] and skin
tumors [47]. On the other hand, CD20 expression has
also been previously evaluated as a predictor of
prognosis in patients with hematological malignancies
[48–50]. Similar to our findings, other authors have re-
ported that CD20 expression is associated with low sur-
vival [48] and therapies directed against CD20, such as
Rituximab, have been implemented in hematological ma-
lignancies [49, 50]. However, controversial studies re-
garding the correlation between the expression of CD20
and prognosis have been published [51–53]. Therefore,
it has been suggested that the prognostic significance of
CD20 in B-ALL should be explored in other prospective
studies with larger sample size.
With regards to the possible mechanism for low treat-
ment response and poor survival of patients with gene ex-
pression signature ID1/ID3/IGJ and over-expression of
CD10 or CD20, the ID1 and ID3 genes are transcription
factors that inhibit of differentiation and have been reported
as important participants in tumorigenic processes, tumor
progression, angiogenesis, cellular migration, epithelial-
mesenchymal transition and tumor cell self-renewal [23,
24, 54–64]. CD10, in turn, in addition to being a useful
marker in cell differentiation to discriminate maturational
stages in B-lineage, has also been described as playing a
fundamental role in the extracellular microenvironment
[44]. Several reports have shown that in various types of
cancer, including hematopoietic tumors, CD10 has high
tumorigenic activity and can promote tumor progression
by regulating gene expression profiles related to cell prolif-
eration, angiogenesis and apoptosis resistance [44, 65, 66].
Furthermore, CD10 promotes tumor stem cells prolifera-
tion and can regulate different intracellular signaling path-
ways that promote survival and adhesion such as PI3K-Akt,
PTEN and adhesion through FAK [66]. Additionally, with
its peptidase activity, CD10 modulates accumulation of
peptides involved in cell proliferation and tumor progres-
sion in prostate, lung and pancreatic cancer [66]. In colo-
rectal cancer, CD10 degrades Met-enkephalin, accelerating
the tumor growth and liver metastasis [66]. Meanwhile,
CD20 is a tetraspanin with ability to form calcium channels
and regulate cell cycle progression and activation, differen-
tiation and proliferation of B cells [67].
Overall, despite gene expression levels show high dis-
persion between patients and differences of ID1/ID3/IGJ
expression between groups 1 and 3 classified based on
immunophenotype is not too big, the high expression of
inhibitors of differentiation (ID1 and ID3) together with
the overexpression of the immaturity marker CD10 and
aberrant expression of CD20, suggest that may there are
active processes blocking differentiation, leading to mat-
uration asynchronism that may confer more aggressive
tumor characteristics and may lead to the activation of
signaling pathways that contribute to resistance to che-
motherapeutic treatment. These findings support the
fact that there are differences in the prognosis of pa-
tients due to an underlying molecular signature
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(immunophenotype + gene expression) that could be
playing an important role in the pathogenesis of the dis-
ease and provides unfavorable characteristics for clinical
outcome.
This study has some limitations, which have to be
pointed out. Due to this work represents only a small part
of the Colombian population with B-ALL the results should
be interpreted with caution since it is possible that factors
other than difference of the expression level of our gene ex-
pression signature and its correlation wit phenotypic
markers may influence the prognosis and outcome of pa-
tients. Additional studies including a larger series of pa-
tients are needed to obtain more significant differences and
confirm the potential use of the ID1/ID3/IGJ as a prognos-
tic marker. Despite the above limitations, this work will be
the subject of ongoing studies.
These results support the utility of EuroFlow immuno-
phenotype of B-ALL cells combined with the assessment
of ID1/ID3/IGJ gene expression as a potential, independ-
ent prognostic indicator in B-ALL for both OS and EFS.
Importantly, determining the expression of these ele-
ments could be used as a powerful yet simple and inex-
pensive prognostic tool. Thus, further screening and
confirmation studies are required to validate our find-
ings and determine whether ID1/ID3/IGJ measurements
should become routine in B-ALL.
Additional files
Additional file 1: Comparative analysis of mean fluorescence channels for
the 19 markers included in the Euroflow panel and the parameters of light
scattering (SSC and FSC) of leukemic cells from 42 B-ALL adult patients
compared to three normal bone marrow samples. The box incorporates the
middle quartiles; the line represents the median value: the whiskers indicate
the minimum and maximum values. There is gain in expression of CD45,
CD10, CD58, CD22, CD66, CD24, CD34, CD19 and FSC, SSC in B-ALL samples
(B-ALL) as compared to normal bone marrow (Normal). There is loss in
expression of CD38, CD117, CD9, TdT in B-ALL samples as compared to
normal bone marrow. * P <0.05 with respect of pre-pre-B normal cells.
(TIFF 910 kb)
Additional file 2: Characteristics of pronostic groups according to
EuroFlow immunophenotype. (TIFF 1364 kb)
Additional file 3: Expression levels of immunophenotypic markers in the
two groups formed at the extremes of heatmap (group 1 and group 3) with
different clinical characteristics. No statistically significant differences were
observed in the expression of CD20, CD58, CD66, CD117, CD34, CD33,
SmIgM, CD13, Lambda, CD9, TdT, CD22, CD24, SSC. (TIFF 1519 kb)
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